A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (<scp>EDG</scp>‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy
Authors
Gilad Gordon
Jeffrey A. Silverman
Ben Barthel
Marc Evanchik
James E. MacDougall
Kevin M. Koch (ORCID: https://orcid.org/0000-0003-4490-9761)
Molly Madden
Michael DuVall (ORCID: https://orcid.org/0000-0001-9938-7468)
A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (EDG‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy
Gilad Gordon, Jeffrey A. Silverman, Ben Barthel, Marc Evanchik et al.
Citations
2 citations
Journal
Muscle & Nerve
Topics
Muscle Physiology and Disorders
Field-Weighted Citation Impact (FWCI)
1.61
article
A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (EDG‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy
Gilad Gordon, Jeffrey A. Silverman, Ben Barthel, Marc Evanchik, James E. MacDougall, Kevin M. Koch, Molly Madden, Michael DuVall, Abby Bronson, Nicole Kilburn, Alan J. Russell, Joanne M. Donovan